Disc Medicine Quarterly Income Statements Chart
Quarterly
|
Annual
Disc Medicine Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | ||||||||||||||||||
| research and development | 46,319,000 | 27,763,000 | 24,797,000 | 24,685,000 | 23,485,000 | 23,704,000 | 22,565,000 | 14,419,000 | 12,100,000 | 20,180,000 | 20,615,000 | 438,000 | 2,580,000 | 9,804,000 | 12,634,000 | 13,455,000 | 10,842,000 | 11,786,000 |
| selling, general and administrative | 15,091,000 | 12,183,000 | ||||||||||||||||
| total operating expenses | 61,410,000 | 39,946,000 | 34,550,000 | 32,856,000 | 30,852,000 | 31,462,000 | 29,714,000 | 18,958,000 | 17,328,000 | 25,125,000 | 21,327,000 | 3,737,000 | 7,234,000 | 15,177,000 | 17,742,000 | 18,450,000 | 16,320,000 | 16,490,000 |
| income from operations | -61,410,000 | -39,946,000 | -34,550,000 | -32,856,000 | -30,852,000 | -31,462,000 | -29,714,000 | -18,958,000 | -17,328,000 | -25,125,000 | -21,327,000 | -3,737,000 | -7,234,000 | -15,177,000 | -17,742,000 | -18,450,000 | -16,320,000 | -16,490,000 |
| yoy | 99.05% | 26.97% | 16.28% | 73.31% | 78.05% | 25.22% | 39.33% | 407.31% | 139.54% | 65.55% | 20.21% | -79.75% | -55.67% | -7.96% | ||||
| qoq | 53.73% | 15.62% | 5.16% | 6.50% | -1.94% | 5.88% | 56.74% | 9.41% | -31.03% | 17.81% | 470.70% | -48.34% | -52.34% | -14.46% | -3.84% | 13.05% | -1.03% | |
| operating margin % | ||||||||||||||||||
| other income, net: | ||||||||||||||||||
| interest income | 7,057,000 | 6,880,000 | 5,838,000 | 6,362,000 | 4,573,000 | 4,519,000 | 4,677,000 | 4,843,000 | 2,910,000 | 2,367,000 | 52,000 | 499,000 | 149,000 | 9,000 | 4,000 | 5,000 | 5,000 | 1,000 |
| interest expense | -910,000 | -897,000 | -38,750 | -41,000 | -48,000 | -66,000 | -85,000 | -104,000 | -121,000 | -1,848,000 | ||||||||
| other income | 68,000 | -3,000 | 3,000 | 9,000 | -13,000 | -1,000 | -10,000 | 13,000 | -5,000 | 12,000 | 2,000 | 43,000 | 3,000 | -2,000 | -11,000 | |||
| total other income | 6,215,000 | 5,980,000 | 5,269,000 | 6,371,000 | 4,560,000 | 4,518,000 | 6,167,000 | 4,856,000 | 1,405,000 | 2,367,000 | ||||||||
| income before income taxes | -55,195,000 | -33,966,000 | -29,281,000 | -26,485,000 | -26,292,000 | -26,944,000 | -23,547,000 | -14,102,000 | -15,923,000 | -22,758,000 | ||||||||
| income tax expense | -52,000 | -119,000 | -176,000 | -114,000 | -60,000 | -5,000 | -32,000 | -20,000 | -24,000 | -23,000 | ||||||||
| net income | -55,247,000 | -34,085,000 | -29,457,000 | -26,599,000 | -26,352,000 | |||||||||||||
| yoy | 109.65% | |||||||||||||||||
| qoq | 62.09% | 15.71% | 10.74% | 0.94% | ||||||||||||||
| net income margin % | ||||||||||||||||||
| net income per share | -1.58 | -1.02 | -0.98 | -0.89 | -1.03 | -1.09 | -0.97 | -0.58 | -0.74 | -1.2 | -44.46 | -0.08 | -0.16 | -0.35 | -0.41 | -0.43 | -0.38 | -0.59 |
| weighted-average common shares outstanding, basic and diluted | 35,024,592 | 33,324,745 | 27,606,022 | 43,264,616 | 43,230,523 | 43,212,803 | 40,362,303 | 43,091,822 | 43,041,856 | 32,027,161 | ||||||||
| comprehensive loss: | ||||||||||||||||||
| other comprehensive income: | ||||||||||||||||||
| foreign currency translation adjustments | -15 | 14 | 15 | -48 | 6 | |||||||||||||
| unrealized loss on marketable securities | -247 | -66 | ||||||||||||||||
| total other comprehensive loss | -262 | -60 | ||||||||||||||||
| comprehensive loss | -55,509 | -33,839 | -29,909 | -25,798 | -26,412 | |||||||||||||
| unrealized gain on marketable securities | 232 | -467 | 849 | |||||||||||||||
| total other comprehensive income | 246 | -452 | 801 | |||||||||||||||
| general and administrative | 5,824,000 | 8,171,000 | 7,367,000 | 7,758,000 | 7,149,000 | 4,539,000 | 5,228,000 | 4,945,000 | 712,000 | 3,299,000 | 4,654,000 | 5,373,000 | 5,108,000 | 4,995,000 | 5,478,000 | 4,704,000 | ||
| change in fair value of contingent value right liability | -375,000 | -1,500,000 | ||||||||||||||||
| net income attributable to common stockholders-basic and diluted | -19,975,000 | -26,599,000 | -26,352,000 | -26,949,000 | -23,579,000 | -14,122,000 | -15,947,000 | -22,781,000 | ||||||||||
| weighted-average common shares outstanding-basic and diluted | 29,935,551,000 | 25,649,043,000 | 24,809,869,000 | 22,315,877,000 | 24,316,817,000 | 21,484,955,000 | 18,954,914,000 | 1,039,490,000 | ||||||||||
| other comprehensive loss: | ||||||||||||||||||
| net income and comprehensive loss | -26,949,000 | -23,579,000 | -14,122,000 | -15,947,000 | -22,781,000 | -21,229,000 | -3,277,000 | -7,090,000 | -15,231,000 | -17,823,000 | -18,551,000 | -16,447,000 | -19,048,000 | |||||
| change in fair value of derivative liability | ||||||||||||||||||
| other income: | ||||||||||||||||||
| loss on conversion of convertible notes | -711,000 | |||||||||||||||||
| change in fair value of warrant liability | ||||||||||||||||||
| net income attributable to common stockholders | -16,447,000 | -19,048,000 |
We provide you with 20 years income statements for Disc Medicine stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Disc Medicine stock. Explore the full financial landscape of Disc Medicine stock with our expertly curated income statements.
The information provided in this report about Disc Medicine stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.